AATMAJ2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AATMAJ 2023-04-01 2024-03-31 INR Half yearly true Cash Flow Indirect Unaudited Standalone 85664000.00 2360000.00 88024000.00 7173000.00 0.00 0.00 11533000.00 5868000.00 3806000.00 28211000.00 56591000.00 31433000.00 0.00 31433000.00 0.00 31433000.00 7700000.00 872000.00 8572000.00 22861000.00 0.00 0.00 0.00 22861000.00 22861000.00 113000000.00 5 1.01 1.01 0.00 0.00 0.00 Notes to Unaudited Standalone Financial Results for the Half Year ended September 30, 2023 1. The above standalone financial results of the company (“the statement”) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at its Meeting held on November 9, 2023 and have been subjected to limited review by the statutory auditors of the company on which the auditors have been expressed an unmodified Opinion. 2. The Standalone Financial results has been prepared in accordance with recognition and measurement principles laid down in the Accounting Standard 25 “Interim Financial Reporting” (As 25) as prescribed under section 133 of the companies act, 2013 (“the Act”) read with the companies (accounting standards) Rules, 2021, as amended from time to time and other accounting principal generally accepted in India. 3. The figures for the Half year ended March 31, 2023 are the balancing figures between audited figures in respect of year ended March 31, 2023 and figures for the half year ended September 30, 2022. 4. The company is engaged primarily in the business of Operating Multi Specialties Hospitals and all its operations are in India only. Accordingly, there is no separate reportable segment as per AS 17 on “Segment Reporting” in respect of Company. 5. The Company applied to National Stock Exchange of India Limited (“NSE”) for in-principle approval for listing its equity shares on the Emerge Platform of the NSE. National Stock Exchange of India Limited has, vide its letter dated June 1, 2023 granted it’s In Principle Approval to the Company. The Company had filed Prospectus to the Registrar of the Company, Ahmedabad on June 13, 2023.The Public Issue was opened on Monday, June 19, 2023 and closed on Wednesday, June 21, 2023. The Basis of Allotment was finalized by Company, Registrar to the issue and merchant banker in consultation with the NSE on June 26, 2023. The Company has applied for listing of its total equity shares to NSE and it has granted its approval vide its letter dated June 28, 2023. The trading of equity shares of the Company commenced w.e.f. June 30, 2023 at Emerge Platform of National Stock Exchange of India Ltd. (NSE). (Rs. In Lacs ) Sr. No. Objects as per Prospectus Allocation as per Prospectus Fund utilised up to September 30, 2023 Balance as on September 30, 2023 1 Repayment/Prepayment in full or part of existing secured debt of the company 900.00 900.00 - 2 Funding the working capital requirements of the company 600.00 600.00 - 3 Purchase of medical equipment for hospitals of our company and/or newly acquired or set up hospitals 913.11 90.00 823.11 4 Our inorganic growth initiatives through acquisitions and other strategic initiatives 620.00 - 620 5 General Corporate Expenses 496.89 218.53 278.36 6 Issue Expenses 310.00 310.00 - Total Rs. In Lacs 3,840.00 2,118.53 1,721.47 6.Previous year’s/period’s figures have been regrouped/reclassified whenever necessary. Other Expenses 28211000.00 5868000.00 3806000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9674000.00 -968000.00 -36056000.00 -91393000.00 -19500000.00 -307000.00 -13776000.00 -162000000.00 -152326000.00 -120893000.00 0.00 0.00 0.00 8572000.00 0.00 -129465000.00 0.00 0.00 -129465000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9320000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9320000.00 0.00 0.00 9320000.00 345204000.00 0.00 0.00 0.00 21232000.00 0.00 5868000.00 0.00 -7520000.00 310584000.00 0.00 0.00 310584000.00 190439000.00 0.00 190439000.00 3169000.00 193608000.00